Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
Featured trial
Hair Loss  

[3] The cause of male-pattern hair loss is a combination of genetics and male hormones; the cause of female pattern hair loss is unclear; the cause of alopecia areata is autoimmune; and the cause of telogen effluvium is typically a physically or psychologically stressful event.

  • 0 views
  • 02 Jun, 2021
  • 1 location
A Study Evaluating The Safety Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

A study evaluating the safety, preliminary efficacy and pharmacokinetics of ipatasertib in combination with atezolizumab and docetaxel in participants with mCRPC previously treated with second-generation AR (Androgen Receptor)-targeted therapy. The study consists of two parts: [1] Part A: Safety run-in cohort of approximately 12 participants; [2] Part B: Expansion cohort …

adenopathy
metastatic hormone refractory prostate cancer
gnrh
hair thinning
prostate cancer
  • 0 views
  • 16 Feb, 2024
  • 18 locations
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency.

bone metastases
prostate cancer
soft tissue lesion
adenocarcinoma
steroid therapy
  • 0 views
  • 16 Feb, 2024
  • 107 locations
Continuous Versus Cyclical OCP Use in PCOS (CCOUP)

The mainstay treatment for females with Polycystic Ovary Syndrome (PCOS) has long been a combination of an oral contraceptive pill or OCP (containing both estrogen and progestin) along with an anti-androgen medication (such as Spironolactone) to not only prevent chronic anovulation but also suppress elevated testosterone levels and its clinical …

Accepts healthy volunteers
  • 0 views
  • 04 Apr, 2022
  • 2 locations
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.

This is a Phase II, open-label, randomized controlled umbrella trial evaluating the efficacy and safety of multiple targeted treatment in patients with metastaticTNBC.

cancer
HER2
solid tumour
triple-negative breast cancer
pyrotinib
  • 0 views
  • 16 Feb, 2024
  • 1 location
Evaluate the Efficacy Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years .

human papillomavirus
cancer
cervical cancer
cervical cap
emergency contraception
  • 0 views
  • 16 Feb, 2024
  • 1 location
EBRT and HDR Brachytherapy for Unfavorable-intermediate High and Very High-risk Prostate Cancer

This study is trying to find out if the combination of Androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment (internal radiation implant procedure) and external beam radiation therapy (EBRT) treatments lead to less side effects.

cancer
brachytherapy
androgens
pelvic mri
antiandrogen therapy
  • 0 views
  • 16 Feb, 2024
  • 1 location
Enzalutamide Treatment in COVID-19

The vast majority of patients needing intensive care are men, and this may be due to the androgens, either by regulation of TMPRSS2, necessary for virus internalization, or other mechanisms. Enzalutamide is an antiandrogen inhibiting the expression of androgen regulated proteins, such as TMPRSS2. The aim of this trial is …

covid-19
enzalutamide
oral contraceptives
  • 0 views
  • 05 Aug, 2020
EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression

This study will evaluate whether a lifestyle intervention focused on weight loss, EMPOWER, reduces prostate cancer progression at 12 months among men with biochemical recurrence following local treatment for prostate cancer. Half of the men will be randomized to receive the EMPOWER intervention, while the other half will receive standard …

testosterone level
definitive treatment
ct scan
prostate cancer
body mass index
  • 0 views
  • 16 Feb, 2024
  • 1 location
Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer

Prostate cancer is the second most common cancer among Canadian men of which approximately 20-30% present with high-risk tumour characteristic. Although surgery can be curative in patients evidencing pathological high-risk disease (extracapsular extension, seminal vesicle involvement, positive surgical margins), a large proportion will develop biochemical failure within years from the …

bone metastases
prostate specific antigen
gonadotrophin
adjuvant
ct scan
  • 0 views
  • 16 Feb, 2024
  • 2 locations